We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+8.65%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$6.63B
AUM Growth
+$825M
Cap. Flow
+$471M
Cap. Flow %
7.11%
Top 10 Hldgs %
82.61%
Holding
140
New
29
Increased
38
Reduced
20
Closed
21

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.1M
2
INCY icon
Incyte
INCY
+$10.5M
3
DNLI icon
Denali Therapeutics
DNLI
+$8.99M
4
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$7.86M
5
ALBO
Albireo Pharma Inc
ALBO
+$7.61M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$33.5M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.4M
3
RXDX
Ignyta, Inc.
RXDX
+$11.1M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$10.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.07M

Sector Composition

Rank Sector Weight
1 Consumer Staples 43.26%
2 Consumer Discretionary 19.67%
3 Healthcare 17.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBIO
76
Crescent Biopharma
CBIO
$546M
$4.2M 0.06%
2,500
+475
+23% +$628K
SPRO icon
77
Spero Therapeutics
SPRO
$68.9M
$4.11M 0.06%
+350,000
New +$4.3M
DVAX
78
DELISTED
Dynavax Technologies
DVAX
$3.74M 0.06%
200,000
+50,000
+33% +$1M
LCTX icon
79
Lineage Cell Therapeutics
LCTX
$264M
$3.35M 0.05%
1,779,708
+314,325
+21% +$686K
TGTX icon
80
TG Therapeutics
TGTX
$8.19B
$3.28M 0.05%
400,000
– –
WVE icon
81
Wave Life Sciences
WVE
$1.12B
$3.23M 0.05%
+92,078
New +$2.68M
RDUS
82
CALL
DELISTED
Radius Health, Inc.
RDUS
$3.18M 0.05%
100,000
-250,000
-71% -$7.84M
STML
83
DELISTED
Stemline Therapeutics, Inc.
STML
$3.12M 0.05%
200,000
-50,000
-20% -$669K
VSTM icon
84
Verastem
VSTM
$529M
$3.07M 0.05%
83,333
+20,833
+33% +$941K
MCRB icon
85
Seres Therapeutics
MCRB
$45.3M
$3.04M 0.05%
15,000
-12,500
-45% -$2.57M
HALO icon
86
Halozyme
HALO
$9.88B
$3.04M 0.05%
+150,000
New +$2.76M
CCXI
87
DELISTED
ChemoCentryx, Inc.
CCXI
$2.98M 0.04%
500,000
– –
CLLS
88
Cellectis
CLLS
$292M
$2.92M 0.04%
100,000
– –
CRBP icon
89
Corbus Pharmaceuticals
CRBP
$165M
$2.84M 0.04%
13,333
+8,333
+167% +$1.78M
AKAO
90
DELISTED
Achaogen Inc
AKAO
$2.69M 0.04%
250,000
– –
BCRX icon
91
BioCryst Pharmaceuticals
BCRX
$2.43B
$2.46M 0.04%
500,000
-150,000
-23% -$727K
CMRX
92
DELISTED
Chimerix, Inc.
CMRX
$2.31M 0.03%
500,000
– –
XNCR icon
93
Xencor
XNCR
$1.45B
$2.19M 0.03%
100,000
– –
ACHN
94
DELISTED
Achillion Pharmaceuticals
ACHN
$2.16M 0.03%
750,000
-250,000
-25% -$908K
TSRO
95
CALL
DELISTED
TESARO, Inc.
TSRO
$2.07M 0.03%
25,000
– –
JNCE
96
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.91M 0.03%
150,000
-50,000
-25% -$735K
MGNX icon
97
MacroGenics
MGNX
$233M
$1.9M 0.03%
100,000
-100,000
-50% -$1.87M
MRTX
98
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.82M 0.03%
+100,000
New +$1.55M
ATYR
99
aTyr Pharma
ATYR
$47.3M
$1.75M 0.03%
35,714
+17,857
+100% +$1.1M
MRNS
100
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.63M 0.02%
+50,000
New +$1.35M
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2017 Portfolio in Review

As of Q4 2017, Artal Group held 140 positions worth $6.63B, up 14% from $5.81B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group deployed $471M of net new capital in Q4 2017, opening 29 new positions and adding to 38 existing holdings. Its largest new stake was Denali Therapeutics: 500,000 shares worth $7.82M.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Nektar Therapeutics, an estimated $33.5M trimmed.

  • Artal Group's largest Q4 2017 buy was Denali Therapeutics: 500,000 shares worth $7.82M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q4 2017, an estimated $25.1M increase.
  • Artal Group's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $33.5M.
  • Artal Group fully exited BioMarin Pharmaceuticals in Q4 2017, selling an estimated $17.4M.
  • Artal Group's ten largest holdings make up 83% of its $6.63B portfolio in Q4 2017.
  • Artal Group opened 29 new positions and closed 21 in Q4 2017.
  • Artal Group's portfolio value rose 14% quarter-over-quarter to $6.63B.

Based on Artal Group's 13F filing for Q4 2017, filed 9 Feb 2018.